

**TITLE PAGE**  
**- Food Science of Animal Resources -**  
**Upload this completed form to website with submission**

1  
2  
3  
4

ARTICLE INFORMATION	Fill in information in each box below
<b>Article Type</b>	Research article
<b>Article Title</b>	Comparison of histology, growth characteristics, gut microbiota, and metabolites in the meat and organs of deoxynivalenol-contaminated piglets
<b>Running Title (within 10 words)</b>	Deoxynivalenol-Induce effects on piglets
<b>Author</b>	Jin Young Jeong <sup>1, †, *</sup> , Junsik Kim <sup>1, †</sup> , Minji Kim <sup>1</sup> , and Seong Hoon Shim <sup>1</sup>
<b>Affiliation</b>	<sup>1</sup> Animal Nutrition and Physiology Division, National Institute of Animal Science, Wanju 55365, Republic of Korea
<b>Special remarks</b> – if authors have additional information to inform the editorial office	† These authors contributed equally to this works
<b>ORCID (All authors must have ORCID) <a href="https://orcid.org">https://orcid.org</a></b>	Jin Young Jeong ( <a href="https://orcid.org/0000-0002-8670-7036">https://orcid.org/0000-0002-8670-7036</a> ) Junsik Kim ( <a href="https://orcid.org/0000-0001-9692-757X">https://orcid.org/0000-0001-9692-757X</a> ) Minji Kim ( <a href="https://orcid.org/0000-0003-2106-1921">https://orcid.org/0000-0003-2106-1921</a> ) Seong Hoon Shim ( <a href="https://orcid.org/0009-0008-5701-2666">https://orcid.org/0009-0008-5701-2666</a> )
<b>Conflicts of interest</b> List any present or potential conflicts of interest for all authors. (This field may be published.)	The authors declare no potential conflict of interest.
<b>Acknowledgements</b> State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available. (This field may be published.)	This research was funded by the Cooperative Research Program for Agriculture, Science, and Technology Development (Project No. PJ015002), Rural Development Administration, Republic of Korea, and the 2024 RDA fellowship program of the National Institute of Animal Sciences, Rural Development Administration, Republic of Korea.
<b>Author contributions</b> (This field may be published.)	Conceptualization: Jeong JY. Data curation: Kim M. Formal analysis: Jeong JY. Methodology: Kim J. Software: Jeong JY. Validation: Shim SH. Investigation: Jeong JY. Writing - original draft: Jeong JY, Kim J. Writing - review & editing: Jeong JY, Kim J, Kim M, Shim SH.
<b>Ethics approval (IRB/IACUC)</b> (This field may be published.)	All the experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the National Institute of Animal Science, Korea (No. NIAS-2020-0479).

5  
6

**CORRESPONDING AUTHOR CONTACT INFORMATION**

For the corresponding author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Jin Young Jeong
Email address – this is where your proofs will be sent	jeong73@korea.kr
Secondary Email address	Jeongjinyoung73@gmail.com
Postal address	Wanju 55365, Republic of Korea
Cell phone number	+82-10-9754-5880
Office phone number	+82-63-238-7487
Fax number	+82-63-238-7497

7  
8

This study aimed to examine the effect of different deoxynivalenol (DON) concentrations on growth performance, histological alterations, fungal populations, and metabolomic profiles in pigs. Twelve weaned piglets were housed in environmentally controlled pens for four weeks. After a week of dietary and environmental adaptation, they were placed in one of the four groups, namely 1) control group, basal diet; 2) T1 group, basal diet supplemented with 1 mg DON/kg feed; 3) T2 group, basal diet supplemented with 3 mg DON/kg feed; and 4) T3 group, basal diet supplemented with 10 mg DON/kg feed. The T3 group was found to have a significantly lower final body weight and average daily gain than the others ( $p < 0.05$ ). As DON concentration levels increased, fibrosis was observed in liver, ileum, and rectum along with the apoptosis of liver cells. However, the gut fungal composition did not show significant differences across the treatments. Collectively, our findings indicated high DON concentrations in pigs to be associated with several adverse effects, including histological changes and growth retardation.

**Keywords:** apoptosis; deoxynivalenol; fibrosis; piglet

## **Introduction**

Mycotoxins are toxic substances produced by fungi that can have detrimental effects on animal health (Abdallah et al., 2015). The majority of these toxins are produced by species belonging to the genera *Aspergillus*, *Fusarium*, and *Penicillium*. Approximately 72% of animal feed worldwide is contaminated with at least one type of mycotoxin (Gruber-Dorninger et al., 2019). In particular, deoxynivalenol (DON) is a trichothecene produced by a species of *Fusarium*. It is one of the most prevalent mycotoxins found in cereal grains, and has been detected in 88% of fodder samples in the Northern Hemisphere (Dolenšek et al., 2021; Holanda and Kim, 2021). In this regard, the United States Food and Drug

34 Administration (USFDA) has set a DON concentration limit of less than 1 mg/kg while the  
35 European Commission has established a similar residual limit of less than 0.9 mg/kg  
36 (European Commission, 2016; Food and Drug Administration, 2010). Studies have  
37 demonstrated that the ingestion of feed contaminated with DON can lead to immune system  
38 problems, gastrointestinal damage, and oxidative stress, which can adversely affect the  
39 survival of farm animals (Pierron et al., 2016; Reddy et al., 2018).

40 Although the risks of DON apply to all farm livestock, pigs are particularly susceptible to  
41 DON toxicity due to the high proportion of grains in their diets and the lack of microbiota that  
42 can degrade mycotoxins in the rumen (Mwaniki et al., 2021; Pierron et al., 2016). Previous  
43 studies had reported that high-DON levels can cause vomiting, diarrhea, and anorexia, which  
44 can cause pigs to feed less and fail to gain weight, resulting in economic losses to pig farms  
45 (Pestka et al., 2017; Wellington et al., 2020). Moreover, DON intake by pigs induces  
46 intestinal damage, which results in reduced absorption and utilization of nutrients (Ghareeb et  
47 al., 2015). This damage may contribute to the poor growth characteristics in pigs (Liu et al.,  
48 2020). Furthermore, reactive oxygen species (ROS) produced by DON can cause apoptosis,  
49 and chronic intake of high levels of DON can induce histological changes, such as fibrosis,  
50 necrosis, and hemorrhage (Skiepko et al., 2020; Weaber et al., 2013).

51 Metabolomics is the comprehensive examination of biological systems with the highest  
52 correlation with phenotypes (Krumisiek et al., 2016; Misra et al., 2017). Metabolomics are  
53 necessary to improve our understanding of mycotoxin-contaminated biological systems. In  
54 this study, specific metabolites in the blood, liver, and other biological samples were used as  
55 biomarkers indicators for monitoring DON contamination.

56 Although all pigs are susceptible to DON, the sensitivity of weaned pigs is greater than that  
57 of growing-finishing pigs (Savard et al., 2015). Studies have demonstrated that DON  
58 ingestion can exacerbate the imbalance in gut microbiota caused by rapid changes in piglet

59 diet, severely affecting the growth of weaned piglets (Liu et al., 2020). We hypothesized that  
60 high-DON levels in this study have deleterious effects on the survival of weaned pigs.  
61 Previous studies had demonstrated that the adverse effects observed in pigs are variable and  
62 correlate with ingested concentrations of DON (Lessard et al., 2015). Consequently, accurate  
63 assess of the DON content in feed ingredients and complete diets is of paramount importance  
64 to mitigate the risk of DON in pig production (Wellington et al., 2020). Therefore, we aimed  
65 to examine the effects of different DON concentrations on growth performance, histological  
66 changes, fungal populations, and metabolomic profiles in pigs.

67

## 68 **Materials and Methods**

### 69 *1. Ethics statement*

70 All animal experimental procedures were reviewed by the Institutional Animal Care and  
71 Use Committee of the National Institute of Animal Science, Korea (No. NIAS-2020-0479).

72

### 73 *2. Animal care and design*

74 Castrated male pigs were obtained from Darby (Anseong, Korea). Twelve pigs (Landrace ×  
75 Yorkshire,  $13.5 \pm 2.3$  kg) were housed in individual pens ( $1.3 \times 2.45$  m). During the study  
76 period, including acclimatization, the housing conditions maintained were a light-dark cycle  
77 of 12:12 h, a room temperature of  $26 \pm 2^\circ\text{C}$  to  $22 \pm 2^\circ\text{C}$ , and a relative humidity of  $55 \pm 5\%$ ,  
78 according to the growth period. The pigs were separated into four distinct categories, namely  
79 1) control group (n = 3), basal diet; 2) T1 group (n = 3), basal diet supplemented with 1 mg  
80 DON/kg feed; 3) T2 group (n = 3), basal diet supplemented with 3 mg DON/kg feed; and 4)  
81 T3 group (n = 3), basal diet supplemented with 10 mg DON/kg feed. The pigs were provided  
82 with food and water *ad libitum* over the course of the study period. A mixed into the diet  
83 using DON (TripleBond, Guelph Ontario, Canada) was carried out in accordance with the

84 established experimental concentrations. The mycotoxin was dissolved in ethyl alcohol (for  
85 alcoholic beverages) equivalent to 1–5% of the diet in a beaker fully sterilized using an  
86 autoclave and stirred until it dissolved completely. The amount of solvent used was  
87 determined thoroughly by preliminary testing to ensure that it did not interfere with the  
88 fluidity of the diet depending on its moisture content. The dissolved toxins were mixed into  
89 the diet at a good mixing ratio using a blender.

90 The pigs were provided with feed that had been contaminated with DON for 28 days. When  
91 the experimental period ends, blood was collected a day before tissue sampling. All animals  
92 were anesthetized using T61. Following exsanguination, the ileum, liver, rectum, urine, and  
93 feces were collected rapidly. The collected samples were rapidly frozen in liquid nitrogen and  
94 stored at -80°C. Additionally, for histological analysis, 10% neutral buffered formalin (NBF;  
95 Sigma-Aldrich, St. Louis, MO, USA) was used for tissue fixation. The following formulae  
96 were employed to determine the average daily gain (ADG), average daily feed intake (ADFI),  
97 and feed conversion ratio (FCR):  $ADG = (\text{final weight} - \text{initial weight}) / \text{age (d)}$ ,  $ADFI =$   
98  $\text{amount of feed provided} - \text{amount of feed remaining}$ ,  $FCR = \text{feed intake}/\text{average daily gain}$ .

### 100 3. Deoxynivalenol content analysis

101 An analysis of the DON content was carried out on DON-containing feeds using ultra-  
102 performance liquid chromatography (UPLC). A 1-gram homogenized DON sample was  
103 extracted with 20 milliliters of distilled water and shaken for 30 minutes. Subsequently, the  
104 extract DON sample (5 mL) was filtered through Whatman No. 1 paper and diluted in 20 mL  
105 of phosphate-buffer saline solution. The extracted sample was loaded separately onto the  
106 appropriate immunoaffinity chromatography columns. UPLC methods and mass spectrometry  
107 were performed as described previously study (Reddy et al., 2021). The amounts of DON in  
108 mixed feed were 0.73 mg/kg, 2.61 mg/kg and 9.52 mg/kg feed, respectively, which are similar

109 to that of the original concentrations. There are no DON contaminations were observed in the  
110 control sample.

111

#### 112 *4. Blood biochemical analysis*

113 A Vacutainer tube was used to collect blood from the jugular vein. Serum was obtained by  
114 centrifugation at 700×g for 15 min and stored at -20°C. A total of 14 parameters were  
115 analyzed, namely alanine aminotransferase (ALT), albumin globulin (ALB), alkaline  
116 phosphatase (ALKP), amylase (AMYL), blood urea nitrogen (BUN), calcium (CA),  
117 cholesterol (CHOL), creatine (CREA), gamma-glutamyl transpeptidase (GGT), glucose  
118 (GLU), lipase (LIPA), phosphate (PHOS), total bilirubin (TBIL), and total protein (TP).  
119 These parameters were determined on a VetTest chemistry analyzer (IDEXX, Westbrook,  
120 ME, USA), according to the manufacturer's instructions.

121

#### 122 *5. Histological analysis*

123 For histological analysis, portions of the ileum, liver, rectum, and meat tissue were  
124 obtained from each of the pigs (0.5 cm x 0.5 cm). The fixed samples in 10% NBF were  
125 embedded in paraffin. The following process was conducted: the fixed samples were  
126 dehydrated in ethanol, starting at 70% ending at 100% EtOH. They were embedded,  
127 sectioned, and heated at 45°C for two hours. For staining, the sections were deparaffinized in  
128 xylene, rehydrated in ethanol, and washed with water. The sections were stained using in-situ  
129 Cell Death Detection Kit (POD) and Masson's trichrome (MT) staining reagent following the  
130 manufacturer's instructions, and observed under a microscope at 200× magnification  
131 (Micrometrics<sup>TM</sup>; Nikon ECLIPSE E200, Japan).

132

133 *6. Library preparation and microbial sequencing*

134 DNA for microbial sequencing was extracted from the cecal and rectal contents using the  
135 DNeasy PowerSoil Kit (12888-100, Qiagen) in accordance with the manufacturer's  
136 instructions. Each sequenced sample is prepared according to the Illumina 16S metagenomic  
137 sequencing library protocols to amplify the V3 and V4 region. The input gDNA 5ng was PCR  
138 amplified with 5x reaction buffer, 1mM of dNTP mix, 500nM each of the universal F/R PCR  
139 primer, and Herculase II fusion DNA polymerase (Agilent Technologies, Santa Clara, CA).  
140 The cycle condition for 1st PCR was 3 min at 95°C for heat activation, and 25 cycles of 30  
141 sec at 95°C, 30 sec at 55°C and 30 sec at 72°C, followed by a 5-min final extension at 72°C.  
142 The universal primer pair with Illumina adapter overhang sequences used for the first  
143 amplifications were as follows: ITS1 5'-  
144 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCC GTA GGT GAA CCT GCG G  
145 -3' ITS4 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCC TCC GCT TAT  
146 TGA TAT GC -3' The 1st PCR product was purified with AMPure beads (Agencourt  
147 Bioscience, Beverly, MA). Following purification, the 2ul of 1st PCR product was PCR  
148 amplified for final library construction containing the index using Nextera XT Indexed  
149 Primer. The cycle condition for 2nd PCR was same as the 1st PCR condition except for 10  
150 cycles. The PCR product was purified with AMPure beads. To achieve the highest quality of  
151 data on Illumina sequencing platforms, it is important to create optimum cluster densities  
152 across every lane of every flow cell. This requires accurate quantification of DNA library  
153 templates, and therefore, we quantified prepared libraries using qPCR following the Illumina  
154 qPCR Quantification Protocol Guide(KAPA Library Quantification kits for Illumina  
155 Sequencing platforms) and qualified using the TapeStation D1000 ScreenTape (Agilent  
156 Technologies, Waldbronn, Germany). The paired-end (2×300 bp) sequencing was performed  
157 using the MiSeq™ sequencer (Illumina, San Diego, USA).

158 *7. Sample preparation and data analysis for LC/MS-based metabolomics*

159 A hundred microliter of serum was combined with 400  $\mu$ L of cold acetone, placed in a  
160 refrigerator, and shaken for 1 h. The 400  $\mu$ L supernatant was decanted, placed in a speed  
161 vacuum to dry completely, followed by dissolution in 100  $\mu$ L of 20% methanol (internal  
162 standard–terfenadine). The resulting solution was analyzed using UPLC-Q-TOF MS (Waters,  
163 USA). The liver, cecum, urine, and fecal samples were lyophilized and extracted as follows:  
164 liver, cecum, and fecal samples were dissolved in 80% methanol with an internal standard  
165 (terfenadine), whereas urine was dissolved in 20% methanol. Upon completion of  
166 metabolomic analysis of each pig sample, the samples were cross-mixed for further analysis.  
167 The samples were injected onto a C18 column using a mobile phase of water with 0.1%  
168 formic acid and acetonitrile. 0.1% formic acid (B) at a flow rate of 0.35 mL/min with an  
169 analysis time of 12–16 min for blood, liver, cecum, feces, and urine at a column temperature  
170 of 40°C. The column was analyzed using Q-TOF MS in ESI mode. TOF-MS data were  
171 scanned between 100 and 1500 m/z with a scan time of 0.2 s. The capillary and sample cone  
172 voltages were 3 and 40 V. The de-solvation flow rate was 800 L/h and the source temperature  
173 was 100°C. Leucine-enkephalin was used as a reference compound. It was analyzed every 10  
174 seconds. A quality control sample was analyzed after every 10 analyses. MS/MS spectra were  
175 obtained using a collision energy ramp (10–45 eV) at m/z 50–1500. The data were processed  
176 using Markerlynx software (Waters), which calculated the mass-to-charge ratio (m/z),  
177 retention time, and ion intensity. The Markerlynx program was used to normalize and align  
178 the LC-MS data obtained using UPLC-Q-TOF MS. Peak-to-peak baseline noise, noise  
179 elimination, peak width, and intensity threshold were used to identify the peaks. The mass  
180 window and retention time window were used to align the metabolite data. All data were  
181 normalized to the standards. Metabolites were identified using a combination of online  
182 databases, literature, and standards.



183 8. *Statistical analysis*

184 The LC/MS data was analyzed using SIMCA-P+ version 12.0.1 (Umetrics, Umea,  
185 Sweden). The results were visualized using PLS-DA. The PLS-DA was evaluated using R2X,  
186 R2Y, Q2, and permutation tests. R2X and R2Y measure how well the model fits the data,  
187 while Q2 measures how well it predicts future data. A permutation test validated the PLS-DA  
188 results. A one-way ANOVA with Duncan's test was used to analyze the relative abundances  
189 of metabolites ( $p < 0.05$ ). Heatmaps of the identified compounds were generated using R. The  
190 heatmaps use a red-white-blue color scale based on the z-score. Red indicates a decrease, blue  
191 indicates an increase, and white indicates no change. The paired-end method generated fastq  
192 files are converted into QIIME2 artifacts, which are available for further analysis.

193 Demultiplexed data was processed using the DADA2 algorithm, including error correction  
194 and removal of rare taxa, to generate representative sequences and a feature table. The  
195 microbial classification of each representative sequence was confirmed by blasting against the  
196 16S rRNA gene database. The Q2-Feature classifier is a Naive Bayes classifier trained based  
197 on the SILVA reference (region V3-V4) database (<https://www.arb-silva.de/>) to classify the  
198 dataset used in the experiment. A resultant table was then used to generate a phylogenetic tree  
199 for downstream alpha and beta analysis. The “core metrics analysis” command was used to  
200 generate Shannon diversity, Pielou’s evenness, observed OTUs and Simpson. ANCOM  
201 analysis was used to verify the differences in feature composition between groups and the  
202 results were visualized. We used Prism 9.5.1 to assess growth performance and biochemical  
203 analyses with one-way ANOVA and Tukey's post hoc test. We presented the results as mean  
204 and standard error of the mean (SEM). We calculated p-values to determine statistical  
205 significance, with a value of less than 0.05 indicating a significant result.

206

207 **Results**

208 *1. Growth performance in piglets contaminated with deoxynivalenol*

209 The effects of DON treatment on piglet growth performance from day 1 to 28 are presented  
210 (Table 1). The initial body weight ( $15.5 \pm 0.17$  kg) did not differ significantly among the  
211 DON-treated groups. However, final body weight ( $27.0 \pm 0.59$  kg) in the T3 group (10 mg/kg)  
212 was significantly lower than the other groups on day 28 ( $p < 0.05$ ). Moreover, the T3 group  
213 exhibited the lowest ADG ( $0.41 \pm 0.02$  kg) and ADFI ( $0.89 \pm 0.02$  kg) for 28 d, with a  
214 tendency for these values being lower than in the other groups ( $p < 0.05$  and  $p = 0.08$ ,  
215 respectively). Feed conversion ratio (FCR) was not significantly affected by DON treatment,  
216 during the experimental period.

217

218 *2. Serum biochemical analysis of piglets fed contaminated deoxynivalenol*

219 Biochemical analysis of the blood samples revealed differences in exposure days and DON  
220 concentrations between the control group and DON-treated groups (Table 2). Analysis of  
221 biochemical parameters demonstrated significant differences in glucose, blood urea nitrogen,  
222 phosphate, calcium, total protein, albumin globulin, globulin, alanine aminotransferase,  
223 alkaline phosphatase, gamma-glutamyl transpeptidase, total bilirubin, and cholesterol levels  
224 across the age groups. Significant differences in ALA and ALKP levels were observed in the  
225 DON treatment groups. Among these parameters, phosphatase levels showed a significant  
226 difference in age and DON interactions ( $p < 0.05$ ). Most of the examined parameters were  
227 within the normal ranges.

228

229 *3. Histological changes in piglets fed contaminated deoxynivalenol*

230 The results of Masson's trichrome staining and TUNEL assay for the analysis of  
231 histological changes in DON-contaminated piglet tissues are presented in Figure 1. The

232 results of our investigation indicated that the degree of fibrosis in the liver, ileum, rectum, and  
233 meat of piglets increased proportionately with the concentration of DON (Figure 1). The  
234 DON-treated groups showed a noticeable increase in histological changes with an increase in  
235 collagen fibers in the liver and meat tissue. The degree of fibrotic progression in groups T1  
236 and T2 was relatively mild while that in T3 group was severely impaired. This group  
237 displayed clear fibrosis with dense fibrotic bands and nodular regeneration of the liver tissue.  
238 The portal vein, artery, and bile duct were stained blue by MT staining in the liver. There was  
239 also blue staining around the lobular boundary. The portal canals and lobular boundaries were  
240 larger, and there was more DON accumulation. The villi and lamina propria of the ileum were  
241 damaged and stained blue more than the control. Rectal tissue analysis revealed that the T1  
242 group exhibited mild fibrosis in the submucosal glands, whereas the T2 and T3 groups  
243 demonstrated moderate fibrosis with more extensive collagen deposition.

244

#### 245 4. Intestinal fungal composition in piglet cecum and rectum

246 To determine the fungal composition of the rectum (n = 12) and cecum (n = 11), samples  
247 were collected from weaned piglets for ITS metagenomic sequencing. Ascomycota (80.7%)  
248 was the predominant phylum in the rectum (Figure 3A), followed by Mucoromycota (15.1%)  
249 and Basidiomycota (4.2%). However, one piglet in the T1 group exhibited disparate results,  
250 with Mucoromycota (93.1%) as the dominant phylum in the rectum. At the genus level,  
251 *Kazachstania* (73.2%) was the dominant genus in the rectum (Figure 3B), followed by *Mucor*  
252 (15.1%), *Candida* (5.2%), and *Apiotrichum* (2.6%). However, one piglet in the T1 group  
253 showed *Mucor* (93.0%) as the most dominant genus in the rectum, and another in the T2  
254 group had *Candida* (52.7%) as the most dominant genus in the rectum (Figure 3B). In the  
255 cecum, across all four groups, Ascomycota (99.9%) was the dominant phylum (Figure 3C),  
256 and *Kazachstania* (99.1%) was the dominant genus (Figure 3D).

257 *5. Multivariate analysis of weaned piglets*

258 Untargeted metabolomics was performed on the blood, liver, cecum, urine, and fecal  
259 samples collected after 28 days from the control group and DON-treated groups (Figure 4).  
260 Metabolomic profiling by LC-MS analysis revealed a clear separation between the control  
261 and DON-contaminated groups in piglets. A total of 1,242 compounds were identified in the  
262 blood (153), liver (261), cecum (268), urine (264), and feces (296). To test the ability of the  
263 metabolome to separate the groups, principal component analysis (PCA) was performed. All  
264 the samples with DON exposure showed an overlap. To further highlight the differences in  
265 metabolomic profiles, the partial least squares discriminant analysis (PLS-DA) score plot  
266 showed good clustering for DON exposure based on qualitative and quantitative data (Figure  
267 4, left panels). Contribution of the metabolite groups to the separation in PCA is shown in the  
268 biplot (Figure 4, middle panels). Characteristics of the OPLS model parameters (R2X, R2Y,  
269 and Q2) were predominantly favorable, except for the blood parameter, which exhibited a  
270 relatively low Q2 value of 0.075. The R2X, R2Y, and Q2 values for the liver tissue were  
271 0.754, 0.979, and 0.745, respectively, for the cecum were 0.406, 0.463, and 0.358,  
272 respectively, for urine were 0.899, 0.980, and 0.898, respectively, and for the feces were  
273 0.761, 0.900, and 0.733, respectively. To determine the effect of the metabolites induced by  
274 DON in the blood, liver, cecum, urine, and feces, a series of metabolites were screened. The  
275 metabolites were randomly divided into distinct categories. The effect of DON treatment was  
276 evident in the heatmap generated for 73 metabolites that were frequently observed in DON-  
277 exposed samples. These clusters showed distinct patterns of altered metabolite abundance  
278 (Figure 4, right panel). The variable importance of projection (VIP) value was set to > 1.0.  
279

280 *5. Comparison of the differentiating compounds in the different tissues*

281 Among the metabolites, the most significant differentiating compounds between the control  
282 and DON groups were as follows: blood (N-Boc-L-2-aminoadipic acid, phenylalanine, N-  
283 retinoylleucine, tetracosaeptaenoic acid, nisinic acid, 5,6-benzoarachidonic acid, ethyl  
284 docosahexaenoate, LPC (P-18:0), LPC (16:0) 2M, and LPC (17:0)); liver (glucose-Na adduct,  
285 deoxyguanosine monophosphate, uric acid, 2-deoxyguanosine, taurodeoxycholic  
286 acid/taurochenodeoxycholic acid fragment, glyoursodeoxycholic  
287 acid/chenodeoxyglycocholic acid 2M, glyoursodeoxycholic acid/chenodeoxyglycocholic  
288 acid, 7-ketoglycolithocholic acid, ethyl docosahexaenoate/nisinic acid, LPC (22:6), and LPC  
289 (17:0)); cecum (L-alpha-glycerolphosphorylcholine, creatine, 7H-purin-8-ol, tyrosine,  
290 phenylalaine, butyrylcarnitine, tryptophan fragment, glyocholic acid, glyoursodeoxycholic  
291 acid /chenodeoxyglycocholic acid fragment, 3-hydroxy-5-cholenoylglycine, 7-  
292 ketoglycolithocholic acid, N-[4-(pentyloxy)benzoyl]valine, 5,6-Benzoarachidonic  
293 acid/Biphen-H2/Dipropofo, ethyl docosahexaenoate/nisinic acid, 7-ketolithocholic  
294 acid/apocholic acid, LPC (14:0), LPC (16:1), LPC (16:0), LPC (18:1), LPC (15:0), LPC  
295 (18:0), LPC (14:1), and LPC (17:0)); urine (4-aminobenzoic acid, Gly-Pro-Glu, 4,5-  
296 Dimethoxy-2-nitrobenzotrile/4-formyl-2-nitroacetanilide, 4-Ethoxy-2-  
297 nitrophenylisocyanate, 6-O-methylguanaine, Dihydroxy-1H-indole glucuronide I, 3-indole  
298 carboxylic acid glucuronide, 5-Hydroxy-6-methoxyindole glucuronide, 6-Hydroxy-5-  
299 methoxyindole glucuronide, Chrysin-7-O-β-D-glucoronide/Daidzein 4'-glucuronide, Daidzein  
300 7-glucuronide, Oroxindin/Oroxilin A glucuronide, Chrysin-7-O-glucuronide/Daidzein  
301 glucuronide, hydroxyquinoline, Baicalin, 1-Naphtylisocyanate/isocyanatonaphthalene, 5-  
302 Hydroxy-2-(3-methoxystyryl)-1-benzofuran-3-carbaldehyde); and feces (threonic acid,  
303 phenylalanine, N-[[1-(L-Alanyl)-4-piperidinyl]carbonyl]-L-isoleucine, tert-butyl 2-(2-  
304 butoxy-2-oxoethyl)-3-oxo-1-piperazinecarboxylate, Carboxyindole, sercobilin, Ginkgolic

305 Acid 17:2, tetracosaeptaenoic acid, norselic acid D/norselic acid B, and tetracosapentaenoic  
306 acid).

307

## 308 **Discussion**

309 This study examined the impact of three different concentrations of DON on growth  
310 characteristics, histology, gut fungi, and metabolomic profiles of weaned piglets over a four-  
311 week period. The results demonstrated that weaned piglets exhibited growth retardation with  
312 increasing DON concentrations (Table 1). The study revealed that DON contamination leads  
313 to fibrosis and apoptosis in specific organs of weaned piglets. Consequently, these findings  
314 emphasized the risks associated with high DON concentrations in piglets, including  
315 histological changes and adverse effects on growth performance. Furthermore, alterations in  
316 the gut fungal community and tissue-specific metabolites have been observed in response to  
317 DON contamination. These results indicated the possibility of identifying potential  
318 biomarkers of DON contamination.

319 The impact of DON on growth performance and nutrient utilization varies across species,  
320 contingent on the duration of exposure, dosage, and the source of contamination (natural or  
321 commercial). The administration of low dosages of naturally DON-contaminated feed at 0.28,  
322 0.54, 0.84, and 1 mg/kg to piglets did not result in any observable effects on their feed  
323 consumption or ADG during the 4 weeks (Jia et al., 2020). The greatest reduction in weight  
324 was observed in pigs fed 5 mg/kg of DON, in comparison to pigs fed 1 and 3 mg/kg of DON,  
325 as evidenced by the results of a six-week trial (Wellington et al., 2020). The administration of  
326 a low dosage of DON via artificial inoculation over a short period of time did not result in any  
327 adverse effects on animal performance, when compared to the effects observed in animals  
328 exposed to natural contamination and high dosages of DON (Dersjant-Li et al., 2003). In  
329 growing pigs, a reduction in ADG and growth performances were observed during the initial

330 week of DON treatment (Li et al., 2018). A separate study demonstrated that dietary  
331 supplementation with DON had no impact on initial body weight. However, growth  
332 performance was affected after four weeks of the experiment (Liu et al., 2018). The findings  
333 suggest that DON contamination (natural vs. commercial) may demonstrate differential  
334 adaptation in pigs. It would appear that there is a paucity of literature examining the direct  
335 effects of ingestion of high concentrations of commercially purified DON on gut and fecal  
336 microbiota composition in piglets. Also, natural mycotoxins did not contain only DON; it is  
337 difficult to obtain a single mycotoxin from nature to know its effectiveness against a single  
338 mold because residue levels are set based on a single mycotoxin. In light of the potential  
339 impact of DON, a commercially purified *Fusarium* mycotoxin, on piglets, this study was  
340 conducted to gain a deeper understanding of its effects.

341 Studies have shown that DON affects the growth characteristics of weaned piglets  
342 negatively (Wang et al., 2018; Xiao et al., 2013). DON can cause severe anorexigenic effects  
343 and vomiting, which can reduce the feed intake in pigs (Holanda and Kim, 2021). This can  
344 lead to intestinal damage, which can reduce the absorption and utilization of nutrients.  
345 (Ghareeb et al., 2015). Body weight loss in pigs can be primarily determined by DON  
346 concentration (Recharla et al., 2022). In this study, Growth performance was not significantly  
347 affected by DON intake below 3 mg/kg. Similarly, Several other studies have reported that  
348 dietary DON levels below 3 mg/kg have no effect on growth performance in pigs (Wellington  
349 et al., 2020; Wu et al., 2015). However, we found that the ADG of the T3 group was reduced  
350 by approximately 13.5% than that of the control group over the course of 28 days, resulting in  
351 the lowest final body weight. Previous studies had reported that high concentrations of DON,  
352 at above 8 mg/kg, decreased the ADG and body weight of pigs, which was in agreement with  
353 our results (Reddy et al., 2018; Wu et al., 2015). Additionally, the ADFI tended to decrease  
354 across the groups depending on DON concentrations, particularly in the T3 group, in which it

355 decreased by approximately 11% compared to that in the control group. These results were  
356 consistent with those of Wang et al. (2018), which suggested a 15.7% decrease in feed intake  
357 and 17.7% decrease in weight gain in weaned piglets that ingested DON for 28 days.  
358 Consequently, the results indicated that the growth retardation was primarily due to decreased  
359 feed intake.

360 Liver is the primary organ responsible for detoxifying and metabolizing DON. Therefore, it  
361 is considered to be the organ most affected by DON (Ruan et al., 2022). In this study, we  
362 observed apoptosis in the different tissue of weaned piglets at high-DON concentrations.  
363 Similarly, Ji et al. (2023) had reported apoptosis in the liver cells of weaned piglets that  
364 ingested feed contaminated with DON. Apoptosis is closely associated with oxidative stress  
365 caused by DON (Kang et al., 2019). Excessive generation of reactive oxygen species (ROS)  
366 by DON can lead to cellular oxidative stress and reduction of antioxidant enzyme activity  
367 (Hou et al., 2021). This can damage the structure and function of mitochondrial membranes,  
368 causing mitochondrial apoptosis in liver tissue (Hou et al., 2021). Oxidative stress-induced  
369 apoptosis in liver cells can activate hepatic stellate cells (HSCs), leading to fibrosis (Lan et  
370 al., 2015). Previous studies had demonstrated that ingestion of DON for 3–6 weeks induces  
371 liver fibrosis in pigs (Skiepko et al., 2020). Similar to previous studies, we found that liver  
372 fibrosis in weaned piglets increased with DON ingestion.

373 Furthermore, our findings indicated that DON causes fibrosis in intestinal tissues, including  
374 the duodenum and rectum. After ingestion of DON-contaminated feed, the intestinal tract of  
375 pigs is the primary target organ, since it serves as the initial physical barrier against feed  
376 contaminants, chemicals, and enteric pathogens (Pasternak et al., 2018; Pierron et al., 2016).  
377 To our knowledge, no previous study had reported intestinal fibrosis due to DON ingestion in  
378 pigs. However, DON is known to cause various histological changes in the intestine. Several  
379 studies have demonstrated that DON ingestion can induce histological damage in the



380 intestine, including multifocal atrophy, villous apical necrosis, enterocyte cytoplasmic  
381 vacuolization, lamina propria edema, and villi fusion (Gerez et al., 2015). Such histological  
382 changes in the intestine caused by mycotoxins result in the loss of the integrity of the  
383 intestinal epithelial barrier and persistent tissue damage, leading to inflammation due to an  
384 excessive immune reaction (Jacobs et al., 2021). This can contribute to the excessive  
385 deposition of extracellular matrix, which can lead to intestinal fibrosis (Jacobs et al., 2021).

386 To our knowledge, only few studies have investigated the effects of DON on intestinal  
387 fungi in pigs. Nevertheless, studies have shown that gut fungi play important roles in various  
388 physiological processes, such as immunity, digestion, and metabolism (Wang et al., 2023). In  
389 the rectum and appendix, no significant variation was observed at the phylum or genus level  
390 between the dietary treatment groups. This can be explained by the observation that fungi  
391 account for only 0.1% of the gut microbiome (Luo et al., 2021). The dominant fungal taxa  
392 found at the phylum level in both rectum and the cecum were *Ascomycota*, *Mucromycota*, and  
393 *Basidiomycota*. This taxonomic composition is similar to that observed in previous studies  
394 that analyzed intestinal fungi in pigs (Kong et al., 2021; Wang et al., 2023). Furthermore, the  
395 dominant genera in the rectum were *Kazachstania*, *Mucor*, *Candida*, and *Apiotrichum*. In the  
396 cecum, *Kazachstania* was the predominant genus. Kong et al. (2021) identified *Derxomyces*,  
397 *Lecanicillium*, *Aspergillus*, and *Simplicillium* as the predominant genera in pigs. These  
398 discrepancies in taxonomic composition may be attributed to regional variations in the gut  
399 microbial composition, which are influenced by the functional diversity of the fecal matter  
400 and the different segments of the gastrointestinal tract (Wang et al., 2023). Furthermore, the  
401 environment, breed, host genotype, and host phenotype can influence the composition of the  
402 gut microbiota (Benson et al., 2010; Li et al., 2020; Pajarillo et al., 2014). In summary, the  
403 results of this study indicated that DON ingestion has no significant effect on the intestinal  
404 fungi in piglets.

405 Previous studies had reported that DON exposure can disrupt a number of biological  
406 processes, including inflammation, immune response, oxidative stress, nutritional regulation,  
407 and programmed cell death (Hao et al., 2021; Lessard et al., 2015; Tang et al., 2021). To  
408 further understand the biological changes observed in the DON-treated groups, metabolomic  
409 analyses were performed. Thus, they reflect an organ or biological system's integrated  
410 response to pathophysiological stimuli (Wishart, 2019). In this study, a variety of metabolites  
411 were identified in blood, liver, cecum, urine, and feces of the DON-treated groups compared  
412 to that in the control. The relative concentrations of most metabolites were lower in the DON  
413 group than in the control, with the exception of those in urine. In other words, the metabolites  
414 in blood, liver, cecum, and feces were either upregulated or downregulated, whereas those in  
415 urine were elevated in the high-DON group (10 mg/kg). Based on these results, we tentatively  
416 suggested an association with urea cycle disorders.

417 Serum cholesterol levels are affected by both feed intake and the rate of fatty acid  
418 production in the liver (Hodson et al., 2020). ALKP is a group of enzymes that facilitate  
419 phosphate hydrolysis (Sharma et al., 2014). ALT is a cytosolic enzyme that is predominantly  
420 expressed in the hepatocytes (Kim et al., 2008). The synthesis of urea from ammonia occurs  
421 in the liver, where it is subsequently excreted by the kidneys (Wang et al., 2014). Various  
422 biological changes are indicated by blood biochemical parameters. In this study, despite the  
423 observation of significant differences in biochemical parameters according to age or DON  
424 concentration, phosphate ( $p$  value for interaction = 0.002) and ALT ( $p$  = 0.03) were one of the  
425 strongest biochemical markers that changed significantly with DON exposure. DON  
426 decreases blood phosphate concentration in male piglets (Sauvé et al., 2023). To enhance the  
427 accuracy of the blood parameters, future studies would require an increase in the number of  
428 animals studied.

429 Urea cycle disorders are a group of rare inherited metabolic disorders caused by a partial or  
430 complete lack of one of the enzymes involved in the urea cycle or the transport proteins that  
431 mediate the urea cycle. These deficiencies result in the accumulation of ammonia and other  
432 nitrogenous compounds (Nagamani et al., 2021). Liver diseases caused by urea cycle  
433 disorders may be characterized by increased serum level of ALT or AST, hepatomegaly,  
434 steatosis, fibrosis, cirrhosis with portal hypertension, and hepatic impairment (Burrage et al.,  
435 2020; Ranucci et al., 2019). A reduction in the level of N-acetyl amino acids may result from  
436 a lack of N-acetyl amino acid synthase or, alternatively, from an inherited mutation in the  
437 coding region of the gene for the enzyme. In either case, this could lead to the development of  
438 metabolic abnormalities and/or diseases. Deficiency in NAcGlu results in urea cycle fails,  
439 causing ammonia to accumulated in the blood without being converted to urea, leading to  
440 Type I Hyperammonemia (Jenkins et al., 2000; Winsberg et al., 2000).

441 The intake of DON has the potential to disrupt the normal functioning of cells by inhibiting  
442 protein synthesis, as well as through the activation of critical cellular kinases, associated with  
443 cell proliferation, differentiation, and apoptosis (Xiao et al., 2013b). For more information on  
444 the effects of DON contamination, metabolic LC-MS fingerprints were generated for the  
445 blood, liver, cecum, urine, and fecal samples of piglets. Although the LC/MS platform was  
446 not able to provide complete coverage of the metabolome, piglets exposed to high-dose DON  
447 showed a significant difference in metabolic profile. Metabolic profiling in mice kidneys and  
448 spleens exposed to 2 mg/kg of DON were identified its impact on immunity function and  
449 nucleotide metabolism (Ji et al., 2017).

450 In conclusion, the purpose of this study was the investigation of the impact of DON  
451 contamination in piglet feed. Anorexia and reduced growth performance in piglets were  
452 induced by a 28-day acute repeated exposure to DON (10 mg/kg). Although the fungal

453 microbiome was not significantly affected, alterations were observed in blood biochemistry  
454 and metabolite concentrations.

455 The histological alterations were observed in the liver, muscle, and other tissues of piglets  
456 exposed to DON for 28 days suggest that this toxin induces dysfunction of these organs. The  
457 method used to assess hepatic dysfunction, which involves the analysis of plasma alanine  
458 aminotransferase (ALT) transaminase, was found to be influential. Although these findings  
459 did not provide a definitive explanation for DON contamination in pigs, additional studies  
460 might provide more accurate indicators. To our knowledge, this was the first report on the  
461 beneficial properties of mycotoxin-induced alterations in gut fungal compositions. However,  
462 whether DON exposure accurately reflects tissue fibrosis in urea cycle disorders is still  
463 unclear. Consequently, additional studies would be required to investigate with more animals  
464 and to reveal the correlation between various biomarkers to assess the presence of  
465 mycotoxins.

## 467 **References**

- 468 1. Abdallah MF, Girgin G, Baydar T. 2015. Occurrence, prevention and limitation of  
469 mycotoxins in feeds. *Anim Nutr Feed Technol* 15(3): 471–490.
- 470 2. Dersjant-Li Y, Verstegen MWA, Gerrits WJJ. 2003. The impact of low concentrations  
471 of aflatoxin, deoxynivalenol or fumonisin in diets on growing pigs and poultry. *Nutr*  
472 *Res Rev* 16: 223–239.
- 473 3. Dolenšek T, Švara T, Knific T, Gombač M, Luzar B, Jakovac-Strajn B. 2021. The  
474 influence of fusarium mycotoxins on the liver of gilts and their suckling piglets.  
475 *Animals* 11(9): 2534.
- 476 4. European Commission. Commission Recommendation (EU) 2016/1319 of 29 July  
477 2016 amending Recommendation 2006/576/EC as regards deoxynivalenol,

- 478 zearalenone and ochratoxin A in pet food. *Off J Eur Union* 208: 58–60.
- 479 5. Food and Drug Administration. Guidance for industry and FDA: Advisory levels for  
480 deoxynivalenol (DON) in finished wheat products for human consumption and grains  
481 and grain-by-products used for animal feed. Available from  
482 [https://www.fda.gov/regulatory-information/search-fda-guidance-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-advisory-levels-deoxynivalenol-don-finished-wheat-products-human)  
483 [documents/guidance-industry-and-fda-advisory-levels-deoxynivalenol-don-finished-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-advisory-levels-deoxynivalenol-don-finished-wheat-products-human)  
484 [wheat-products-human](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-and-fda-advisory-levels-deoxynivalenol-don-finished-wheat-products-human). Accessed at May 22. 2019.
- 485 6. Gerez JR, Pinton P, Callu P, Grosjean F, Oswald IP, Bracarense APF. 2015.  
486 Deoxynivalenol alone or in combination with nivalenol and zearalenone induce  
487 systemic histological changes in pigs. *Exp Toxicol Pathol* 67(2): 89–98.
- 488 7. Ghareeb K, Awad WA, Böhm J, Zebeli Q. 2015. Impacts of the feed contaminant  
489 deoxynivalenol on the intestine of monogastric animals: poultry and swine. *J Appl*  
490 *Toxicol* 35(4): 327–337.
- 491 8. Gruber-Dorninger C, Jenkins T, Schatzmayr G. 2019. Global mycotoxin occurrence in  
492 feed: A ten-year survey. *Toxins* 11(7): 375.
- 493 9. Holanda DM, Kim SW. 2021. Mycotoxin occurrence, toxicity, and detoxifying agents  
494 in pig production, with an emphasis on deoxynivalenol. *Toxins* 13(2): 171.
- 495 10. Holanda DM, Kim YI, Parnsen W, Kim SW. 2021. Phytobiotics with adsorbent to  
496 mitigate toxicity of multiple mycotoxins on health and growth of pigs. *Toxins* 13(7):  
497 442.
- 498 11. Hou S, Ma J, Cheng Y, Wang H, Sun J, Yan Y. 2023. The toxicity mechanisms of  
499 DON to humans and animals and potential biological treatment strategies. *Crit Rev*  
500 *Food Sci Nutr* 63(6): 790–812.
- 501 12. Jacobs I, Ceulemans M, Wauters L, Breynaert C, Vermeire S, Verstockt B, Vanuytsel  
502 T. 2021. Role of eosinophils in intestinal inflammation and fibrosis in inflammatory

- 503            bowel disease: an overlooked villain? *Front Immunol* 12: 754413.
- 504            13. Ji X, Tang Z, Zhang F, Zhou F, Wu Y, Wu D. 2023. Dietary taurine supplementation  
505            counteracts deoxynivalenol-induced liver injury via alleviating oxidative stress,  
506            mitochondrial dysfunction, apoptosis, and inflammation in piglets. *Ecotoxicol Environ*  
507            *Saf* 253: 114705.
- 508            14. Jia R, Liu W, Zhao L, Cao L, Shen Z. 2020. Low doses of individual and combined  
509            deoxynivalenol and zearalenone in naturally moldy diets impair intestinal functions via  
510            inducing inflammation and disrupting epithelial barrier in the intestine of piglets.  
511            *Toxicol Lett* 333: 159–169.
- 512            15. Kang R, Li R, Dai P, Li Z, Li Y, Li C. 2019. Deoxynivalenol induced apoptosis and  
513            inflammation of IPEC-J2 cells by promoting ROS production. *Environ Pollut* 251:  
514            689–698.
- 515            16. Kong Q, Liu S, Li A, Wang Y, Zhang L, Iqbal M, Jamil T, Shang Z, Suo LS, Li J. 2021.  
516            Characterization of fungal microbial diversity in healthy and diarrheal Tibetan piglets.  
517            *BMC Microbiol* 21(1): 204.
- 518            17. Lan T, Kisseleva T, Brenner DA. 2015. Deficiency of NOX1 or NOX4 prevents liver  
519            inflammation and fibrosis in mice through inhibition of hepatic stellate cell activation.  
520            *PLoS One* 10(7): e0129743.
- 521            18. Lessard M, Savard C, Deschene K, Lauzon K, Pinilla VA, Gagnon CA, Lapointe J,  
522            Guay F, Chorfi Y. 2015. Impact of deoxynivalenol (DON) contaminated feed on  
523            intestinal integrity and immune response in swine. *Food Chem Toxicol* 80: 7–16.
- 524            19. Li X, Guo Y, Zhao L, Fan Y, Ji C, Zhang J, Ma Q. 2018. Protective effects of *Devosia*  
525            *sp.* ANSB714 on growth performance, immunity function, antioxidant capacity and  
526            tissue residues in growing-finishing pigs fed with deoxynivalenol contaminated diets.  
527            *Food Chem Toxicol* 121: 246–251.

- 528 20. Liu M, Zhang L, Chu XH, Ma R, Wang YW, Liu Q, Zhang NY, Karrow, NA, Sun LH.  
529 2020. Effects of deoxynivalenol on the porcine growth performance and intestinal  
530 microbiota and potential remediation by a modified HSCAS binder. *Food Chem*  
531 *Toxicol* 141: 111373.
- 532 21. Luo Y, Li J, Zhou H, Yu B, He J, Wu A, Huang Z, Zheng P, Mao X, Yu J, Li H, Wang  
533 H, Wang Q, Yan H, Chen D. 2021. The nutritional significance of intestinal fungi:  
534 alteration of dietary carbohydrate composition triggers colonic fungal community  
535 shifts in a pig model. *Appl Environ Microbiol* 87(10): e00038-21.
- 536 22. Mwaniki AW, Buis QR, Trott D, Huber LA, Yang C, Kiarie EG. 2021. Comparative  
537 efficacy of commercially available deoxynivalenol detoxifying feed additives on  
538 growth performance, total tract digestibility of components, and physiological  
539 responses in nursery pigs fed diets formulated with naturally contaminated corn. *Transl*  
540 *Anim Sci* 5(2): txab050.
- 541 23. Pasternak JA, Aiyer VIA, Hamonic G, Beaulieu AD, Columbus DA, Wilson HL. 2018.  
542 Molecular and physiological effects on the small intestine of weaner pigs following  
543 feeding with deoxynivalenol-contaminated feed. *Toxin* 10(1): 40.
- 544 24. Pestka JJ, Clark ES, Schwartz-Zimmermann HE, Berthiller F. 2017. Sex is a  
545 determinant for deoxynivalenol metabolism and elimination in the mouse. *Toxins* 9(8):  
546 240.
- 547 25. Pierron A, Alassane-Kpembi I, Oswald IP. 2016. Impact of two mycotoxins  
548 deoxynivalenol and fumonisin on pig intestinal health. *Porcine Health Manag* 2: 21.
- 549 26. Recharla N, Park S, Kim M, Kim B, Jeong JY. 2022. Protective effects of biological  
550 feed additives on gut microbiota and the health of pigs exposed to deoxynivalenol: a  
551 review. *J Anim Sci Technol* 64(4): 640–653.
- 552 27. Reddy KE, Kim M, Kim KH, Ji SY, Baek Y, Chun JL, Jung HJ, Choe C, Lee HJ, Kim

- 553 M, Lee SD. 2021. Effect of commercially purified deoxynivalenol and zearalenone  
554 mycotoxins on microbial diversity of pig cecum contents. *Anim Biosci* 34(2): 243–255.
- 555 28. Reddy KE, Song J, Lee HJ, Kim M, Kim DW, Jung HJ, Kim B, Lee Y, Yu D, Kim  
556 DW, Oh YK, Lee SD. 2018. Effects of high levels of deoxynivalenol and zearalenone  
557 on growth performance, and hematological and immunological parameters in pigs.  
558 *Toxins* 10(3): 114.
- 559 29. Ruan H, Wang Y, Hou Y, Zhang J, Wu J, Zhang F, Sui M, Luo J, Yang M.  
560 Zearalenone-14-Glucoside is hydrolyzed to zearalenone by  $\beta$ -glucosidase in  
561 extracellular matrix to exert intracellular toxicity in KGN cells. *Toxins* 14(7): 458.
- 562 30. Savard C, Provost C, Alvarez F, Pinilla V, Music N, Jacques M, Gagnon CA, Chorfi  
563 Y. 2015. Effect of deoxynivalenol (DON) mycotoxin on in vivo and in vitro porcine  
564 circovirus type 2 infections. *Vet Microbiol* 176(3-4): 257–267.
- 565 31. Skiepkó N, Przybylska-Gornowicz B, Gajęcka M, Gajęcki M, Lewczuk B. 2020.  
566 Effects of deoxynivalenol and zearalenone on the histology and ultrastructure of pig  
567 liver. *Toxins* 12(7): 463.
- 568 32. Wang S, Yang J, Zhang B, Wu K, Yang A, Li C, Zhang J, Zhang C, Rajput SA, Zhang  
569 N, Sun L, Qi D. 2018. Deoxynivalenol impairs porcine intestinal host defense peptide  
570 expression in weaned piglets and IPEC-J2 cells. *Toxins* 10(12): 541.
- 571 33. Wang T, Liu J, Luo Y, Yu B, Kong X, Zheng P, Huang Z, Mao X, Yu J, Luo J, Yan H,  
572 He J. 2023. Combined effects of host genetics and diet on porcine intestinal fungi and  
573 their pathogenic genes. *Front Microbiol* 14: 1192288.
- 574 34. Weaver AC, See MT, Hansen JA, Kim YB, De Souza AL, Middleton TF, Kim SW.  
575 2013. The use of feed additives to reduce the effects of aflatoxin and deoxynivalenol  
576 on pig growth, organ health and immune status during chronic exposure. *Toxins* 5(7):  
577 1261–1281.



- 578 35. Wellington MO, Bosompem MA, Petracek R, Nagl V, Columbus DA. 2020. Effect of  
579 long-term feeding of graded levels of deoxynivalenol (DON) on growth performance,  
580 nutrient utilization, and organ health in finishing pigs and DON content in biological  
581 samples. *J Anim Sci* 98(12): skaa378.
- 582 36. Wu L, Liao P, He L, Ren W, Yin J, Duan J, Li T. 2015. Growth performance, serum  
583 biochemical profile, jejunal morphology, and the expression of nutrients transporter  
584 genes in deoxynivalenol (DON)-challenged growing pigs. *BMC Vet Res* 11: 144.
- 585 37. Xiao H, Wu MM, Tan BE, Yin YL, Li TJ, Xiao DF, Li L. 2013. Effects of composite  
586 antimicrobial peptides in weanling piglets challenged with deoxynivalenol: I. Growth  
587 performance, immune function, and antioxidation capacity. *J Anim Sci* 91(10): 4772–  
588 4780.
- 589 38. Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, Zhang M, Oh PL, Nehrenberg  
590 D, Hua K, Kachman SD, Moriyama EN, Walter J, Peterson D.A, Pomp D. 2010.  
591 Individuality in gut microbiota composition is a complex polygenic trait shaped by  
592 multiple environmental and host genetic factors. *Proc Natl Acad Sci* 107(44): 18933–  
593 18938.
- 594 39. Pajarillo EA, Chae JP, Balolong MP, Kim HB, Seo KS, Kang DK. 2014.  
595 Pyrosequencing-based analysis of fecal microbial communities in three purebred pig  
596 lines. *J Microbiol* 52(8): 646–651.
- 597 40. Sauv e B, Chorfi Y, Montminy ML, Guay F. 2023. Vitamin D supplementation impacts  
598 calcium and phosphorus metabolism in piglets fed a diet contaminated with  
599 deoxynivalenol and challenged with lipopolysaccharides. *Toxins* 15(6): 394.
- 600 41. Lessard M, Savard C, Deschene K, Lauzon K, Pinilla VA, Gagnon CA, Lapointe J,  
601 Guay F, Chorfi Y. 2015. Impact of deoxynivalenol (DON) contaminated feed on  
602 intestinal integrity and immune response in swine. *Food Chem Toxicol* 80: 7–16.

- 603 42. Tang M, Yuan D, Liao P. 2021. Berberine improves intestinal barrier function and  
604 reduces inflammation, immunosuppression, and oxidative stress by regulating the NF-  
605  $\kappa$ B/MAPK signaling pathway in deoxynivalenol-challenged piglets. *Environ Pollut*  
606 289: 117865.
- 607 43. Hao Y, Xing M, Gu X. 2021. Research progress on oxidative stress and its nutritional  
608 regulation strategies in pigs. *Animals* 11(5): 1384.
- 609 44. Wishart DS. 2019. Metabolomics for investigating physiological and  
610 pathophysiological processes. *Physiol Rev* 99(4): 1819–1875.
- 611 45. Nagamani SCS, Ali S, Izem R, Schady D, Masand P, Shneider BL, Leung DH, Burrage  
612 LC. 2021. Biomarkers for liver disease in urea cycle disorders. *Mol Genet Metab*  
613 133(2): 148–156.
- 614 46. Burrage LC, Madan S, Li X, Ali S, Mohammad M, Stroup BM, Jiang MM, Cela R,  
615 Bertin T, Jin Z, Dai J. 2020. Chronic liver disease and impaired hepatic glycogen  
616 metabolism in argininosuccinate lyase deficiency. *JCI Insight* 5(4): e132342.
- 617 47. Ranucci G, Rigoldi M, Cotugno G, Bernabei SM, Liguori A, Gasperini S, Goffredo  
618 BM, Martinelli D, Monti L, Francalanci P, Candusso M, Parini R, Dionisi-Vici C. 2019.  
619 Chronic liver involvement in urea cycle disorders. *J Inherit Metab Dis* 42(6): 1118–  
620 1127.
- 621 48. Bigot A, Tchan MC, Thoreau B, Blasco H, Maillot F. 2017. Liver involvement in urea  
622 cycle disorders: a review of the literature. *J Inherit Metab Dis* 40(6): 757–769.
- 623 49. Kölker S, Valayannopoulos V, Burlina AB, Sykut-Cegielska J, Wijburg FA, Teles, EL,  
624 Zeman J, Dionisi-Vici C, Barić I, Karall D, Arnoux JB, Avram P, Baumgartner MR,  
625 Blasco-Alonso J, Boy, SP, Rasmussen MB, Burgard P, Chabrol B, Chakrapani A,  
626 Chapman K, Saladelafont ECI, Couce ML, de Meirleir L, Dobbelaere D, Furlan F,  
627 Gleich F, González MJ, Gradowska W, Grünewald S, Honzik T, Hörster F, Ioannou H,

628           Jalan A, Häberle J, Haege G, Langereis E, de Lonlay P, Martinelli D, Matsumoto S,  
629           Mühlhausen C, Murphy E, de Baulny HO, Orte C, Pedrón, CC, Pintos-Morell G,  
630           Quintana L, Ramadža DP, Rodrigues E, Scholl-Bürgi S, Sokal E, Summar ML,  
631           Thompson N, Vara RR, Pinera IV, Walter JH, Williams M, Lund AM, Garcia-Cazorla  
632           A. 2015. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part  
633           2: the evolving clinical phenotype. *J Inherit Metab Dis* 38(6): 1059–1074.

634           50. Mori T, Nagai K, Mori M, Nagao M, Imamura M, Iijima M, Kobayashi K. 2002.  
635           Progressive liver fibrosis in late-onset argininosuccinate lyase deficiency. *Pediatr Dev*  
636           *Pathol* 5(6): 597–601.

637           51. Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA. 2000.  
638           Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. *Biol*  
639           *Psychiatry* 47(6): 475–481.

640           52. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal  
641           MF. 2000. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of  
642           neuronal loss and increases in glutamine and glucose in transgenic Huntington's  
643           disease mice. *J Neurochem* 74(5): 2108–2119.

644

645  
646

**Table 1.** Growth performance of weaned piglets with increasing DON intake<sup>1</sup>

	Control 0 mg/kg	T1 1 mg/kg	T2 3 mg/kg	T3 10 mg/kg	SEM	pvalue
Initial BW <sup>2</sup> , kg	15.5	15.5	15.5	15.5	0.17	0.9999
Final BW <sup>3</sup> , kg	31.2 <sup>a</sup>	30.1 <sup>a</sup>	30.9 <sup>a</sup>	27.0 <sup>b</sup>	0.59	0.0118
ADFI, kg	1.00	0.93	0.97	0.89	0.02	0.0772
ADG, kg	0.56 <sup>a</sup>	0.52 <sup>a</sup>	0.55 <sup>a</sup>	0.41 <sup>b</sup>	0.02	0.0313
FCR	1.79	1.80	1.76	2.26	0.10	0.3393

647  
648  
649  
650  
651  
652  
653  
654  
655

BW, body weight; ADFI, average daily feed intake; ADG, average daily gain; FCR, feed conversion ratio; SEM, standard error of the mean

<sup>1</sup> CTL, basal diet; T1, basal diet + 1 mg DON/kg feed; T2, basal diet + 3 mg DON/kg feed; T3, basal diet + 10 mg DON/kg feed.

<sup>2</sup> Measured on day 1 after one week of adaptation.

<sup>3</sup> Measured on day 28 after one week of adaptation.


<sup>a,b</sup> Different superscripts indicate that the variables within a row are significantly different ( $p < 0.05$ ),  $n = 12$

**Table 2.** Biochemical analysis of serum from DON-contaminated piglets


Blood parameters	Interval	Control 0 mg/kg	T1 1 mg/kg	T2 3 mg/kg	T3 10 mg/kg	p value		
						Day	DON	Day x DON
Glucose, mg/dL	1 d	113.33±14.26	118.33±0.88	120.00±4.58	124.67±5.46	p<0.001	0.44	0.47
	5 d	100.67±1.76	103.00±4.73	92.33±4.63	108.33±1.45			
	28 d	108.67±6.33	94.33±1.33	92.33±7.86	101.33±4.37			
Creatinine, mg/dL	1	0.87±0.03	0.73±0.03	0.83±0.09	0.70±0.06	0.08	0.1	0.1
	5	0.77±0.09	0.70±0.06	0.80±0.06	0.73±0.03			
	28	0.80±0.06	0.70±0.06	0.80±0.06	1.03±0.09			
Blood urea nitrogen, mg/dL	1	4.33±0.33	3.67±0.33	3.67±0.33	4.00±0.00	p<0.001	0.15	0.75
	5	3.67±0.33	3.33±0.33	4.00±0.00	4.33±0.33			
	28	5.67±1.20	5.00±1.00	4.33±0.58	6.67±0.33			
BUN/CREA ratio	1	7.00±2.52	5.33±0.67	4.67±0.88	6.00±0.58	0.24	0.62	0.94
	5	5.00±1.00	5.00±1.00	5.00±0.58	6.00±0.00			
	28	7.33±1.86	7.67±2.33	5.33±0.88	6.67±0.88			
Phosphate, mg/dL	1	8.97±0.38 <sup>c</sup>	11.00±0.23 <sup>ab</sup>	10.40±0.15 <sup>b</sup>	10.00±0.21 <sup>b</sup>	p<0.001	0.16	0.002
	5	11.00±0.21 <sup>b</sup>	12.33±0.41 <sup>a</sup>	11.23±0.72 <sup>b</sup>	10.57±0.69 <sup>ab</sup>			
	28	11.10±0.15 <sup>b</sup>	9.83±0.27 <sup>b</sup>	11.23±0.31 <sup>b</sup>	11.00±0.23 <sup>ab</sup>			
Calcium, mg/dL	1	8.97±0.30	11.00±0.26	10.40±0.18	10.00±0.12	0.002	0.45	0.11
	5	11.00±0.12	12.33±0.31	11.23±0.10	10.57±0.10			
	28	11.10±0.18	9.83±0.10	11.23±0.21	11.00±0.07			
Total protein, g/dL	1	5.33±0.07	5.70±0.10	5.40±0.18	5.97±0.15	p<0.001	0.17	0.31
	5	5.97±0.27	6.40±0.15	6.27±0.10	6.60±0.10			
	28	6.80±0.60	6.00±0.15	6.27±0.21	6.63±0.35			
Albumin globulin, g/dL	1	2.37±0.07	2.90±0.10	2.63±0.12	2.80±0.06	0.01	0.56	0.16
	5	2.80±0.21	3.13±0.18	3.03±0.18	3.03±0.12			
	28	3.37±0.47	2.93±0.15	3.00±0.12	3.10±0.15			
Globulin, g/dL	1	2.97±0.13	2.80±0.10	2.77±0.18	3.17±0.19	0.003	0.05	0.87
	5	3.17±0.07	3.27±0.18	3.23±0.12	3.57±0.13			

ALB/GLOB ratio	28	3.43±0.15	3.07±0.15	3.27±0.12	3.53±0.34	0.94	0.29	0.21
	1	0.77±0.07	1.00±0.06	0.97±0.03	0.87±0.07			
	5	0.90±0.06	0.97±0.07	0.93±0.03	0.87±0.07			
Alanine aminotransferase, U/L	28	1.00±0.10	0.93±0.07	0.90±0.03	0.87±0.09	p<0.001	0.03	0.69
	1	109.33±16.59	84.33±6.84	92.00±6.03	70.00±8.08			
	5	119.00±5.51	103.00±5.13	128.33±11.84	101.00±1.53			
Alkalinephosphatase, U/L	28	148.67±18.49	109.00±9.17	144.00±21.80	135.67±24.83	0.006	0.004	0.28
	1	264.33±23.10	236.00±22.07	330.33±21.71	273.67±25.12			
	5	285.00±19.09	350.00±24.42	404.67±17.90	333.33±8.17			
Gamma glutamyl transpeptidase, U/L	28	293.67±5.84	269.00±16.62	358.00±63.32	363.67±25.44	p<0.001	0.1	0.52
	1	20.00±1.73	14.00±1.15	19.67±4.48	21.33±3.84			
	5	16.00±4.36	19.00±1.00	23.33±1.45	21.67±5.61			
Total bilirubin, mg/dL	28	23.67±1.20	30.00±2.65	25.00±2.08	33.00±1.15	0.03	0.44	0.11
	1	0.10±0.00	0.13±0.03	0.10±0.00	0.23±0.03			
	5	0.17±0.03	0.30±0.10	0.37±0.22	0.33±0.19			
Cholesterol, mg/dL	28	1.20±0.62	0.30±0.06	0.40±0.07	0.33±0.09	0.004	0.06	0.51
	1	72.67±5.55	86.33±7.42	85.00±5.77	75.00±3.21			
	5	88.00±5.51	97.67±6.64	102.33±7.31	98.33±11.86			
Amylase, U/L	28	82.00±2.08	90.67±5.46	101.67±12.57	110.33±7.31	0.56	0.17	0.81
	1	853.33±70.74	601.33±176.73	685.33±49.33	622.67±100.40			
	5	774.33±45.11	729.00±184.60	1051.00±147.29	636.33±163.05			
Lipase, U/L	28	792.00±14.18	662.67±204.32	878.33±177.00	653.33±157.75	0.07	0.71	0.87
	1	17.67±4.26	23.67±6.94	30.33±10.17	25.67±11.46			
	5	47.67±20.63	52.33±15.17	98.00±9.54	80.00±46.87			
	28	39.00±11.79	78.33±61.34	76.00±24.68	49.00±25.32			

Values are mean ± SEM; n = 12. Normal range value: GLU (85–160), CREA (0.5–2.1), BUN (6–30), PHOS (3.6–9.2), CA (6.5–11.4), TP (6.0–8.0), ALB (1.8–3.3), GLOB (2.5–4.5), ALT (9–43), ALKP (92–294), GGT (16–30), TBIL (0.1–0.3), CHOL (18–79), AMYL (271–1198), LIPA (10–44). GLU: glucose; CREA: creatinine; BUN: blood urea nitrogen; PHOS: phosphate; CA: calcium; TP: total protein (TP= ALB + GLOB); ALB, albumin globulin; GLOB, globulin; ALT, alanine aminotransferase; ALKP, alkaline phosphatase; GGT, gamma glutamyl transpeptidase; TBIL, total bilirubin; CHOL, cholesterol; AMYL, amylase; LIPA, lipase. All characteristics in the table were analyzed using one-way ANOVA with Tukey's multiple comparison test.




**Figure 1.** Histological analysis of DON-contaminated piglet tissues. Images of the liver, ileum, and rectum of weaned piglets on day 28 of the trial using Masson's Trichrome (blue) staining according to DON concentrations. In all three organs, normal tissue appearance was observed in the control group, whereas increasing collagen deposition was observed with increasing deoxynivalenol (DON) concentration. Control: basal diet; T1: basal diet + 1 mg DON/kg feed; T2: basal diet + 3 mg DON/kg feed; T3: basal diet + 10 mg DON/kg feed. Sections are shown with 200× magnification and the blue stained areas of fibrosis are marked with yellow arrows.




**Figure 2.** Representative images of apoptosis (black arrows) in the liver cells of weaned piglets on day 28 of the trial using TUNEL staining according to deoxynivalenol (DON) concentrations. The T3 group showed an increase in TUNEL-positive staining compared to the control group. Control, basal diet; T1, basal diet + 1 mg DON/kg feed; T2, basal diet + 3 mg DON/kg feed; T3, basal diet + 10 mg DON/kg feed. Sections are shown at 200× magnification.







(A) Phylum



(B) Genus




(C) Phylum



(D) Genus

**Figure 3.** Gut fungal taxonomic profiles of weaned piglets. **(A)** Rectal fungal composition at the phylum level (n = 12). **(B)** Rectal fungal composition at the genus level (n = 12). **(C)** Cecal fungal composition at the phylum level (n = 11). **(D)** Cecal fungal composition at the genus level (n = 11). C, Control group fed basal diet; T1, basal diet + 1 mg DON/kg feed; T2, basal diet + 3 mg DON/kg feed; T3, basal diet + 10 mg DON/kg feed.

ACCEPTED



**Figure 4.** Metabolite profiling of blood, liver, cecum, urine, and feces from piglets fed diets contaminated with DON for 28 days. (A–E) PLS-DA score plot (left), biplot (middle), and heatmap (right) for each of the five tissue types. Variations in score plots were defined using a

95% confidence interval. The biplot from the PLS-DA shows the scores of the samples and the loading of variables. The heatmap shows the significantly different data visualization of multiple parameters for the potential indicators of VIPs ( $VIPs > 1, P < 0.05$ ). In the PLS-DA and biplots, the colored and white circles represent the metabolites identified in the DON-contaminated piglet tissue groups.

ACCEPTED